The Future of Pharma Patents: Recent Trends and Challenges (RECORDING)

Renée Fuller is Senior Corporate Counsel in the Innovation Law Group at BMS and provides strategic counseling on all facets of patent and innovation law. Prior to BMS, Renée worked in-house at MyoKardia, Inc. and in private practice at Wolf, Greenfield & Sacks, where she focused on global patent procurement and strategy, transactions, diligence, and contested matters. Renée earned a B.S. in Chemistry from UNC-Chapel Hill, Ph.D. in Chemistry and Biomedical Engineering from MIT, and J.D. from Suffolk University Law School and completed a postdoctoral fellowship in Chemistry at Harvard University.

James Sanner is a senior associate at Leydig, Voit & Mayer, Ltd. in Chicago. James focuses his practice on patent litigation, including Hatch-Waxman litigation, and also handles contested proceedings before the Patent Trial and Appeal Board and International Trade Commission. James holds a J.D. from the University of Illinois College of Law, a master's degree in Microbiology and Molecular Genetics from Rutgers University, and a bachelor's degree in Molecular and Cellular Biology from the University of Illinois at Urbana-Champaign.

Steven H. Sklar is a shareholder with Leydig, Voit & Mayer, Ltd. Steve has more than 27 years of experience representing clients in patent litigation in the pharmaceutical and biotechnology fields, in particular Hatch-Waxman litigation. Steve regularly advises on clients on issues of infringement, validity, and enforcement of pharmaceutical patents.  His many successes include a recent victory, both at trial and on appeal to the Federal Circuit, in litigation involving a leading opioid addiction treatment drug product. Steve graduated magna cum laude with a B.S. in Chemical Engineering from Washington University in St. Louis and earned his law degree cum laude from the Northwestern University School of Law.